AI Article Synopsis

  • Epigenetic modifications significantly influence how the Epstein-Barr virus (EBV) genes are expressed, particularly through the role of EZH2, a key enzyme in histone modification.
  • Research showed that knocking out the EZH2 gene in EBV-negative B cells led to slower cell growth post-infection and increased expression of viral genes during the lytic phase.
  • The findings highlight EZH2's importance in regulating both latent and lytic gene expression of EBV, suggesting it may serve as a form of innate immunity to control viral replication.

Article Abstract

Epigenetic modifications play a pivotal role in the expression of the genes of Epstein-Barr virus (EBV). We found that EBV infection of primary B cells caused moderate induction of enhancer of zeste homolog 2 (EZH2), the major histone H3 lysine 27 (K27) methyltransferase. To investigate the role of EZH2, we knocked out the EZH2 gene in EBV-negative Akata cells by the CRISPR/Cas9 system and infected the cells with EBV, followed by selection of EBV-positive cells. During the latent state, growth of EZH2-knockout (KO) cells was significantly slower after infection compared to wild-type controls, despite similar levels of viral gene expression between cell lines. After induction of the lytic cycle by anti-IgG, KO of EZH2 caused notable induction of expression of both latent and lytic viral genes, as well as increases in both viral DNA replication and progeny production. These results demonstrate that EZH2 is crucial for the intricate epigenetic regulation of not only lytic but also latent gene expression in Akata cells. The life cycle of EBV is regulated by epigenetic modifications, such as CpG methylation and histone modifications. Here, we found that the expression of EZH2, which encodes a histone H3K27 methyltransferase, was induced by EBV infection; therefore, we generated EZH2-KO cells to investigate the role of EZH2 in EBV-infected Akata B cells. Disruption of EZH2 resulted in increased expression of EBV genes during the lytic phase and, therefore, efficient viral replication and progeny production. Our results shed light on the mechanisms underlying reactivation from an epigenetic point of view and further suggest a role for EZH2 as a form of innate immunity that restricts viral replication in infected cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262262PMC
http://dx.doi.org/10.1128/mSphere.00478-18DOI Listing

Publication Analysis

Top Keywords

akata cells
16
role ezh2
12
ezh2
10
cells
10
epstein-barr virus
8
life cycle
8
histone h3k27
8
h3k27 methyltransferase
8
epigenetic modifications
8
ebv infection
8

Similar Publications

A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection.

Front Immunol

January 2025

Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.

Background: Epstein-Barr virus (EBV) is a significant global public health concern because of its association with various malignancies and autoimmune diseases. Over 90% of the global population is chronically infected with EBV, impacting numerous cancer-related cases annually. However, none of the effective prophylactic vaccines against EBV is approved at present.

View Article and Find Full Text PDF

Epstein-Barr virus (EBV) co-infections with human papillomavirus (HPV) have been observed in oropharyngeal squamous cell carcinoma. Modeling EBV/HPV co-infection in organotypic epithelial raft cultures revealed that HPV16 E7 inhibited EBV productive replication through the facilitated degradation of the retinoblastoma protein pRb/p105. To further understand how pRb is required for EBV productive replication, we generated CRISPR-Cas9 pRb knockout (KO) normal oral keratinocytes (NOKs) in the context of wild-type and mutant K120E p53.

View Article and Find Full Text PDF

Unlabelled: Epstein-Barr virus (EBV) is a ubiquitous human tumor virus that establishes lifelong, persistent infections in B cells. The presence of EBV in cancer cells presents an opportunity to target these cells by reactivating the virus from latency. In this study, we developed a novel approach for EBV reactivation termed clustered regularly interspaced short palindromic repeats (CRISPR)/dCas9-mediated EBV reactivation (CMER) strategy.

View Article and Find Full Text PDF

After Epstein-Barr virus (EBV) genome replication and encapsidation in the nucleus, nucleocapsids are translocated into the cytoplasm for subsequent tegumentation and maturation. The EBV BGLF4 kinase, which induces partial disassembly of the nuclear lamina, and the nuclear egress complex BFRF1/BFLF2 coordinately facilitate the nuclear egress of nucleocapsids. Here, we demonstrate that within EBV reactivated epithelial cells, viral capsids, tegument proteins, and glycoproteins are clustered in the juxtanuclear concave region, accompanied by redistributed cytoplasmic organelles and the cytoskeleton regulator IQ-domain GTPase-activation protein 1 (IQGAP1), close to the microtubule-organizing center (MTOC).

View Article and Find Full Text PDF

GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway.

Nat Immunol

February 2024

Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Article Synopsis
  • Researchers aim to extend human healthspans by keeping cells functional and non-senescent, as aging appears to be genetically regulated in model organisms.
  • A new human genetic disease linked to GIMAP5 deficiency leads to cell senescence, liver and immune dysfunction, and early death, highlighting GIMAP5's importance in longevity.
  • GIMAP5 helps regulate the accumulation of harmful long-chain ceramides by interacting with a protein kinase (CK2), and targeting CK2 can restore function in GIMAP5-deficient cells, showing its role in maintaining immune health and longevity.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!